Colony-stimulating factors improve neoadjuvant immunochemotherapy efficacy in non-small-cell lung cancer without EGFR or ALK mutations: A double-center real-world retrospective study

Read full text Summarise with VIRAT
Authors: Yan Huang, Xirui Lin, Zhichao Li, Caiyan Fang, Jiyang Chen, Xiuying Xie, Hansheng Wu, Weidong Wang, Hong Yang, Jianhua Fu
Cited by: 0
References: 44

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Preclinical evidence suggests colony-stimulating factors (CSFs) may modulate antitumor immunity. This study evaluated granulocyte colony-stimulating factor (G-CSF) administration on neoadjuvant immunochemotherapy (NICT) efficacy in non-small-cell lung cancer (NSCLC) without EGFR or ALK mutations. METHODS: In this double-center retrospective study (2019-2025), 439 stage II/III NSCLC patients without EGFR or ALK mutations receiving NICT followed by R0 resection were analyzed. Propensity score matching (PSM, 1:1) balanced baseline characteristics between G-CSF (n = 135) and control groups (n = 304), yielding 114 matched pairs. Primary endpoints included pathological complete response (PCR) and survival outcomes. RESULTS: G-CSF administration during NICT significantly improved PCR rates (G-CSF vs. Control: unmatched 39.8% vs 26.7%, p = 0.011; PSM 43.9% vs. 28.1%, p = 0.019). The 2-year disease-free survival (DFS) was comparable between the two groups (unmatched: 81% vs. 79%; PSM: 79% vs 75%, p > 0.05). Multivariate analysis identified G-CSF as an independent factor for PCR in PSM cohort (OR = 2.09, 95%CI 1.19-3.72, p = 0.011), but not as an independent factor for DFS (p > 0.05). Tuberculosis, histological grade and adjuvant therapy were significant prognostic factors for DFS (p < 0.05). CONCLUSIONS: For NSCLC patients without EGFR or ALK mutations receiving NICT, G-CSF administration could enhance PCR rates. Prospective trials evaluating G-CSF and GM-CSF combined with PD-1 inhibitors are warranted.

Fields of Study & Subjects

Lung Cancer Diagnosis and Treatment Lung Cancer Research Studies Lung Cancer Treatments and Mutations

Publication details

Journal / source
Lung Cancer
Volume
215
Pages
109380–109380
Publication date
22 March 2026
Language
EN